---
title: Reduce tremor and movement fluctuations
nct_id: NCT06909045
phase: NA
status: RECRUITING
sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06909045"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06909045"
last_fetched: "2026-05-10T14:08:20.145Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor and movement fluctuations

**Goal (in five words):** Reduce tremor and movement fluctuations

**Official Title:** Randomized Controlled Trial Comparing Adaptive Versus Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

**Trial ID:** [NCT06909045](https://clinicaltrials.gov/study/NCT06909045)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Target Enrollment:** 130 participants
- **Start Date:** 2026-01-27
- **Completion Date:** 2027-02-01
- **Conditions:** Deep Brain Stimulation, Parkinson Disease
- **Interventions:** Adaptive DBS, Continue DBS
- **Intervention Types:** OTHER

## Summary For Families

The goal is to see if adaptive stimulation of the subthalamic nucleus, which responds in real time to abnormal brain signals, controls motor symptoms and side effects better than the usual continuous DBS. Adaptive DBS uses the implanted Medtronic Percept system to monitor beta-band activity in the STN and automatically raise or lower stimulation when pathological beta rhythms appear, delivering stimulation only when needed; continuous DBS delivers a steady level all the time, and adaptive DBS is meant to work alongside levodopa and other meds rather than replace them. The trial is looking for adults 18 and older with idiopathic Parkinson's who already have bilateral Percept PC/RC STN leads, show a reliable beta peak in at least one STN, can recognize their ON/OFF motor states, can consent and understand Dutch; people with dementia, pregnancy, or participation in other neurological intervention trials are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of idiopathic PD based on the UK Brain Bank criteria (Hughes et al. 1992);
* Age older than 18 years;
* Previous implantation of Medtronic PerceptTM PC/RC DBS electrodes bilateral targeting the STN;
* Optimal contact point compatible with aDBS in at least one STN;
* Reliable beta peak in at least one STN;
* Able to provide informed consent and comply with the study protocol;
* Understand the Dutch language.

Exclusion Criteria:

* Legally incompetent adults;
* Patients with ongoing participation in other clinical trials involving neurological interventions;
* Inability to recognize the difference between the motor ON or OFF state;
* Mild cognitive impairment or dementia;
* Pregnancy.
```

## Locations (4)

- UZ Leuven, Leuven, Belgium _(50.8796, 4.7009)_
  - B. Swinnen, MD, PhD — (SUB_INVESTIGATOR)
- Amsterdam UMC, Amsterdam, Netherlands _(52.3740, 4.8897)_
  - Martijn Beudel, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Maastricht UMC+, Maastricht, Netherlands _(50.8483, 5.6889)_
  - M.L.F. Janssen, MD, PhD — (SUB_INVESTIGATOR)
- HagaZiekenhuis, The Hague, Netherlands _(52.0767, 4.2986)_
  - M.F. Contarino, MD, PhD — (SUB_INVESTIGATOR)

## Central Contacts

- M. Beudel, MD, PhD — (CONTACT) — +31 20 566 9111 — closepd@amsterdamumc.nl

---

*Canonical: https://parkinsonspathways.com/trial/NCT06909045*  
*HTML version: https://parkinsonspathways.com/trial/NCT06909045*  
*Source data: https://clinicaltrials.gov/study/NCT06909045*